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Abstract 
The aim of present study was to prepare controlled release trazodone hydrochloride 
matrix tablets. The dissolution profiles at three pHs were carried out for 24 hrs to 
monitor release of drug from tablets. The effect of three variables, drug, HPMC, and 
A vicel contents, on the release of drug from the matrix was evaluated using a full 23 
factorial design. T 50 and T 90 (time to release 50% and 90% drug respectively) were 
used as response parameters to study the effect of three variables mentioned above. 
The effect of tablet size was also studied by comparing the release from matrix-mini 
tablets and matrix tablet, which were made from the same formulation contents. The 
effect of three variables on the release of drug from the matrix was more evident on 
T 90 rather than T 50. The percentage of drug release was slower at higher level of drug 
and HPMC and lower level of Avicel. Among the three variables, the amount of drug 
has significant effect on drug release. Even though drug release from the matrix 
tablets was closer to zero-order, 100% of the drug was not released completely. 
Matrix tablets have longer T50 and T90 compared to matrix-mini tablets. The 
experimental design was shown to b e very useful in determining the direction for 
further optimization in order to achieve zero-order release. 
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1. INTRODUCTION 
1.1 Trazodone hydrochloride 
Trazodone hydrochloride (1.2,4-Triazolo [ 4,3- a] pyridin-3(2H)-one, 2-[3-[ 4-(3-
chlorophenyl)-1-piperazinyl] propyl]- mono hydrate) is an antidepressant agent 
structurally not related to the tricyclics, tetracyclic or monoamine oxidase inhibitors. 
It is a relatively specific but weak serotonin reuptake inhibitor, with minimal effects 
on dopamine and norepinephrine reuptake (Calkin et al. 1998). Therapeutic oral doses 
of trazodone in adult patients have ranged from 50 to 600 mg/day. Most patients 
respond to 100 to 300 mg/day in single or divided doses (Rawls 1982). Trazodone is 
used primarily in the treatment of mental depression or depression/anxiety disorders. 
The drug has also shown some efficacy in the treatment of benzodiazepine or alcohol 
dependence, diabetic n europathy, and panic disorders. T razodone has proven to be 
both safe and effective in elderly patients, having less adverse influence on cognitive 
and performance skills than arnitryptiline (Bayer et al. 1989). 
Trazodone has consistently been found to significantly improve insomnia, with little 
tolerance developing to its hypnotic effect. Trazodone improves sleep not only in 
major depressive disorder and dysthmic disorder but also in chronic primary insomnia 
associated with other anti- depressant medications (Calkin et al. 1998). 
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Trazodone has 89% to 95% plasma protein bonding and is rapidly and completely 
absorbed from the gastrointestinal tract. The drug is metabolized in the liver and 
excreted primarily in urine. The mean half-life is 4 to 7.5 hours. Therapeutic response 
may be seen within 3 to 7 days although optimal effects are seen after 2 to 6 weeks. 
Trazodone possesses a low incidence of of anticholinergic effects and produces 
minimal cardiovascular effects. However, ventricular arrythrnias, hypotension, and 
heart block have occurred. Other adverse effects include drowsiness, weight gain, 
blurred vision, dizziness, and priapism. 
Cl 
.HCl 
Figure 1: Chemical structure of trazodone hydrochloride 
1.2 Controlled release dosage form 
During the past two decades, significant advances have been made in the area of 
controlled release as evidenced by an increasing number of patents, publications, as 
2 
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well as commercial controlled release products for the delivery of a variety of 
pharmaceutical compounds. This proliferation of interest is a reflection of the 
growing awareness that by achieving predictable and reproducible release rates of 
bioactive agents, particularly pharmaceuticals, to the target environment for a desired 
duration, optimum biological responses, compliance by patients, prolonged efficacy, 
decreased toxicity as well as reduction of required dose level as compared to the 
conventional mode of delivery can be effectively achieved (Lee et al. 1987). 
Controlled release drug delivery system is capable of achieving, (1) maintenance of 
optimum therapeutic drug concentration in the blood with minimum fluctuation; (2) 
predictable and reproducible release rates for extended duration; (3) enhancement of 
activity duration for short half life drugs; ( 4) elimination of side effects, frequent 
dosing, and waste of drug; (5) optimized therapy and better patient compliance (Lee et 
al. 1987). 
1.3 Oral delivery 
Historically, the most convenient and commonly employed method of drug delivery 
has been oral ingestion. There are many obvious reasons for this, not the least of 
which would include acceptance by the patient and ease of administration. The types 
of sustained release and controlled release systems employed for oral administration 
include virtually every known theoretical mechanism for such applications. This is 
because there is more flexibility in dosage design, since constraints such as sterility 
and potential damage at the site of administration, are reduced (Banker et al. 1996). 
3 
1.4 Classification of controlled drug release polymeric systems 
Because of the relative ease of production and cost, as compared with other methods 
of sustained or controlled delivery, dissolution and diffusion-controlled systems have 
classically been of primary importance in oral delivery of medication. Dissolution 
based systems have been some of the oldest and most successful oral systems in early 
attempts to market sustaining products. Controlled release systems have been 
classified into the following categories: (1) Diffusion controlled systems (2) 
Chemically controlled systems (3) Swelling controlled systems ( 4) Magnetically 
controlled systems ( 5) Osmotically controlled devices (Langer et al. 1981) ( 6) 
Bioadhesive systems and (7) Gastric retention devices to control GI transit (Florence 
et al. 1994). 
DIFFUSION CONTROLLED SYSTEMS 
These systems are further classified into reservoir systems and matrix systems. 
Membrane-reservoir devices, where the drug core is surrounded by a rate-controlling 
membrane, a re often employed in the area of controlled release pharmaceuticals. In 
the solution-diffusion mechanism, the drug transport occurs by fust dissolving in the 
membrane at one interface followed by diffusion down a chemical potential gradient 
across the membrane and eventually released from the second interface into the 
external medium. Under steady state conditions, a membrane device having a 
saturated drug reservoir can maintain a constant thermodynamic activity gradient 
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across the membrane for an extended period of time. As a result, a constant rate of 
drug release is established. The rate of release from such a system is generally 
dependent on the device geometry and the nature, thickness, and area of the 
membrane, whereas the duration of the release is governed by the size of the drug 
reservolf. 
Membrane reservolf systems based on solution-diffusion mechanism have been 
utilized in different forms for the controlled delivery of therapeutic agents. These 
systems include microcapsules, liposomes, and hollow fibers (Lee et al. 1987). 
In the matrix type of diffusion control systems, the drug is uniformly distributed 
throughout the polymer matrix and is released from the matrix at a uniform rate as 
drug particles dislodge from the polymer network. Unlike the reservoir, there is no 
accidental rupture oft he membrane (Ranade 1990). Some of the materials used for 
matrix systems are insoluble, erodible materials such as camauba wax, stearyl alcohol, 
stearic acid, polyethylene glycol, castor wax (Lachman et al. 1987), hydrophilic 
materials such as methyl cellulose, hydroxypropyl methyl cellulose (Ford 1999), 
hydroxy ethylcellulose, sodium carboxymethyl cellulose, sodium alginate, 
carageenans and insoluble inert materials such as polyethylene, polyvinyl chloride, 
methyl acrylate, ethylcellulose, etc., (Lachman et al. 1987). 
CHEMICALLY CONTROLLED SYSTEMS 
These systems are classified in to two types (i) Bioerodible systems (ii) Pendant chain 
systems. In the Bioerodible system, the controlled release of drugs involves polymers 
5 
that gradually decompose. The drug is dispersed uniformly throughout the polymer 
and is slowly released as the polymer disintegrates. Two major advantages of 
bioerodible systems are (1) polymers do not have to be removed from the body after 
the drug supply is exhausted; and (2) the drug does not have to be water-soluble. 
In Pendant chain systems a drug molecule is chemically linked to the backbone of the 
polymer. In the body, in presence of enzymes or fluids, chemical hydrolysis or 
enzymatic cleavage occurs with concomitant release of the drug at a controlled rate 
(Ranade. 1990). 
SWELLING CONTROLLED SYSTEMS 
Swelling controlled release of potent drugs may be achieved by employing the 
glassy/rubbery transition of polymers in the presence of a penetrant, and the 
macromolecular relaxations associated with this transition. In these systems the drug is 
dispersed in a glassy polymer. There is no drug diffusion in the solid phase. As the 
dissolution medium penetrates the matrix, the polymer swells and its glass transition 
temperature is lowered below the temperature of the experiment. Therefore, the 
swollen polymer is in a rubbery state and it allows the drug contained in it to diffuse 
outwards (Langer et al. 1981). 
Hydrogels: Hydrogels are defined as a polymeric material, which have the ability to 
swell in water without dissolving and to retain water within its structure. They are 
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generally described as two compartment systems. One compartment being hydrophilic 
insoluble, three-dimensional network and other being water (Swarbick et al. 1988). 
The h ydrophilicity oft he polymer imparts water-attracting properties to the system. 
Their characteristic water-insoluble behavior is attributed to the presence of chemical 
or physical cross-links, which provide a network structure and physical integrity to the 
system. Hydrogels are elastic in nature because of the presence of a memorized 
reference configuration to which they return even after being deformed for a long 
period of time (Silberberg 1989). Preparation of a hydrogel-based drug product 
involves either cross-linking of linear polymers or simultaneous polymerization of 
monofunctional monomers and cross-linking with polyfunctional monomers 
(Bouwstra et al. 1993). Polymers from natural, synthetic or semi-synthetic sources can 
be used for synthesizing hydrogels. Usually, polymers containing hydroxyl, amine, 
amide, ether, carboxylate and sulfonate as functional groups in their side chains are 
used. 
MAGNETICALLY CONTROLLED SYSTEMS 
Magnetically controlled targeted drug delivery systems are aimed at concentrating 
drugs at defined site (Gupta et al 1989). In these systems, drug and small magnetic 
beads are uniformly dispersed within a polymer matrix. Upon exposure to aqueous 
media, drug is released in a fashion typical of diffusion-controlled matrix systems 
(Langer et al. 1981). Two major advantages of the magnetically responsive carrier 
system over other drug delivery systems are high efficiency for in vivo targeting and 
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its controllable release of drugs at the microvascular level. A magnetically controlled 
delivery mechanism has been used to deliver anti-tumor agents, antibiotics, insulin, 
and fibrinolytic agents (Ranade. 1990). 
OSMOTICALLY CONTROLLED DEVICE 
Osmotic pressure was first employed as an energy source to deliver active ingredients 
in the 1950s (Rose et al. 1955). Because pharmaceutical agents can be delivered in a 
controlled pattern over a long period by osmotic pressure, there has been increasing 
interest in the development of osmotic devices in the past two decades. The 
elementary osmotic pump (EOP) was introduced by Theeuwes in the 1970s. The EOP 
consists of an osmotic core, with the drug surrounded by a semipermeable membrane 
drilled with a delivery orifice. In operation, the osmotic core acts by imbibing water 
from the surrounding medium via the semipermeable membrane. Subsequently, drug 
solution was generated within the device and delivered out of the device via the 
orifice. The EOP is very simple to prepare and releases drug at an approximate zero-
order rate (Theeuwes et al. 1972). However, the generic EOP is only suitable for the 
delivery of water-soluble drugs. 
To overcome the limit of EOP, a push-pull osmotic tablet was developed in the 1980s. 
Adalat® nifedipine tablet is a commercialized push-pull osmotic tablet product made 
by Pfizer. The push-pull osmotic tablet consists of two compartments, one containing 
drug and the other an osmotic agent and an expandable agent. 'A semipermeable 
membrane that regulates water influx into both compartments surrounds the system. 
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An orifice was drilled into the surface of the drug compartment to allow drug release 
(Theeuwes et al. 1984). While the push-pull osmotic tablet succeeds in delivering 
water-insoluble drug, it has two disadvantages: (1) the tablet core is prepared by 
compressing two kinds of compartments together, a complex technology as compared 
with that of monolithic tablets; and (2) after coating, a complicated laser-drilling 
technology should be employed to drill the orifice next to the drug compartment 
(Geerke 1997). 
BIOADHESIVE SYSTEMS AND GASTRIC RETENTION DEVICES TO 
CONTROL GI TRANSIT 
Floating drug delivery systems 
Floating drug delivery systems (FDDS), also known as hydrodynamically balanced 
systems (HBS), are currently utilized in the prolongation of the gastric residence times 
(GRT). FDDS or hydrodynarnically balanced systems have a bulk density lower than 
gastric fluids and thus remain buoyant in the stomach without affecting the gastric 
emptying rate for a prolonged period of time. While the system is floating on the 
gastric contents, the drug is released slowly at a desired rate from the system. After the 
release of drug, the residual system is emptied from the stomach. This results in an 
increase in the GRT and a better control of fluctuations in plasma drug concentrations 
in some cases (Singh et al. 1999). 
Based on the mechanism of buoyancy, two distinctly different technologies, i.e., 
noneffervescent and effervescent systems, have been utilized in the development of 
FDDS. 
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Noneffervescent FDDS 
The most commonly used excepients in noneffervescent FDDS are gel-forming or 
highly swellable cellulose type hydrocolloids, polysaccharides, and matrix forming 
polymers such as polycarbonate, polyacrylate, polymethacrylate and polystyrene. One 
of the approaches to the formulation of such floating dosage forms involves intimate 
mixing of drug with a gel-forming hydrocolloid, which swells in contact with gastric 
fluid after oral administration and maintains a relative integrity of shape and a bulk 
density of less than unity within the outer gelatinous barrier (Hilton et al 1986). The 
air trapped by the swollen polymer confers buoyancy to these dosage forms . In 
addition, the gel structure acts as a reservoir for sustained drug release since the drug 
is slowly released by a controlled di ffusion through the gelatinous barrier. 
Effervescent FDDS 
These buoyant delivery systems utilize matrices prepared with swellable polymers 
such as Methocel® or polysaccharides, e.g., chitosan, and effervescent components, 
e.g., sodium bicarbonate and citric or tartaric acid (Rubinstein et al. 1994). The 
matrices are fabricated so that upon arrival in the stomach, carbon dioxide is liberated 
by the acidity oft he gastric con tents and is entrapped in the g ellified h ydrocolloid. 
This produces an upward motion of the dosage fom1 and maintains its buoyancy. A 
decrease in specific gravity causes the dosage form to float on the chyme (Rubinstein 
et al. 1994). The carbon dioxide generating components may be intimately mixed 
within the tablet matrix, in which case a single-layered tablet is produced (Hashim et 
10 
al. 1987), or a bilayered tablet may be compressed which contains the gas generating 
mechanism in one hydrocolloid containing layer and the drug in the other layer 
formulated for a SR effect (Ingani et al. 1987). 
Bio (mucoadhesive) gastrointestinal drug delivery systems: 
Mucoadhesion involves the attachment of a natural or synthetic polymer to a 
biological substrate. It is a practical method of drug immobilization or localization and 
an important new aspect of controlled drug delivery. In recent years there has been an 
increased interest in mucoadhesive polymers for drug delivery (Peppas et al. 1985). 
A mucoadhesive controlled-release device can improve the effectiveness of a 
treatment by helping to maintain the drug concentration between the effective and 
toxic levels, inhibiting the dilution of the drug in the body fluids, and allowing 
targeting and localization of a drug at a specific site. 
Mucoadhesion also increases the intimacy and duration of contact between a drug-
containing polymer and a mucous surface. It is believed that the mucoadhesive nature 
of the device can increase the residence time of the drug in the body. The combined 
effects of the direct drug absorption and the decrease in excretion rate allow for an 
increased bioavailability of the drug with a smaller dosage and less frequent 
administration (Huang et al. 2000). 
An advantage of using a mucoadhesive polymer earner for drug delivery is the 
prevention of first-pass metabolism of certain protein drugs by the liver through the 
introduction of the drug via a route bypassing the digestive tract. Drugs that are 
11 
absorbed through the mucosal lining of tissues can enter directly into the bloodstream 
and not be inactivated by enzymatic degradation in the gastrointestinal tract (Park et al 
1984). A polymeric device allows for slow, controlled, and predictable drug release 
over a period of time and hence reduces the overall amount of drug needed. 
1.5 Purpose of the study 
The conventional tablets of trazodone hydrochloride available in the United States are 
50mg, 1 OOmg, 150mg, and 300mg. Controlled release tablets provide desired plasma 
levels within therapeutic window over a long period of time. The incidence of local 
and systematic side effects frequently observed after the intake of immediate release 
dosage forms will be reduced by controlled release tablets. The encapsulated matrix 
mini-tablet approach has the advantages of multiparticles (pellets) such as reduced risk 
of dose dumping, minimal food effect, and flexibility of adjusting dosage strengths. 
Further more, mini-tablets are easier to manufacture compared to the coated 
multiparticulate systems. Factorial design may be useful for screening purposes or as 
an aid in identifying individual effects in complex systems. The factorial design shows 
interaction between factors that ·a 'one at a time' model cannot reveal (Vastraj et al. 
2002). 
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2. EXPERIMENTAL 
2.1 MATERIALS 
1. Trazodone Hydrochloride, Batch# 921473 
Orion Corporation, Espoo, Finland. 
2. Hydroxypropyl methylcellulose K4M Premium CR, Lot# 0125012N12 
The Dow Chemical Company, Midland, MI 4867 4 
3. Avicel PH 102. Lot# 2205 
FMC Corporation, Newark, DE 19711. 
4. Magnesium Stearate, Lot# 742748 
Fisher Scientific, Fair Lawn, NJ 07410. 
5. Cab-0-Sil, Lot# 11238 
Cabot Corporation, Tuscola, IL 61953. 
6. Sodium Phosphate Tribasic, Lot # M50204 
Spectrum Quality Products Inc., New Brunswic, NJ 08901. 
7. Hydrochloric Acid, Lot# 932379 
Fisher Chemical, Fair Lawn, J 07410 
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2.2 EQUIPMENT 
1. USP Dissolution Apparatus I, Model # 11-7000 
Vankel Industries, Cary, NC 27513. 
2. Hewlett Packard 8541 A Diode Array Spectrophotometer 
Hewlett Packard Company, Corvallis, OR. 
3. Carver Laboratory Press, Model# C 
Fred. S. Carver Inc., Menomonee Falls, WI 53051 
4. pH Meter, Model # IQ 240 
IQ Scientific Instruments Inc. , San Diego, CA 92127 
5. Magnetic Stirrer, Model# A 338436 
Fisher Scientific, Fair Lawn, NJ 07410. 
6. Turbula Mixer, Model# lPH 
Turbula, Basel, Switzerland. 
7. Analytical Balance, Model # AE-240S 
Mettler Instrument Corporation, Hightown, NJ 
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2.3 METHODS 
2.3.1 CONSTRUCTION OF THE CALIBRATION CURVE OF TRAZODONE 
HYDROCHLORIDE 
Serial concentrations of trazodone hydrochloride in 0.1 N HCl buffer (pH 1.2), 
phosphate buffers (pH 5 and pH 7 .4) having concentrations between 0-150 mcg/ml 
were prepared. The absorbance of the prepared solutions was measured 
spectrophotometrically at Amax 312 run. The absorbance was plotted against the 
concentration and regression lines were calculated. 
2.3.2 PREPARATION OF TRAZODONE HYDRCHLORIDE TABLETS 
Mixing: Trazodone hydrochloride, hydroxy propyl methylcellulose (HPMC), Avicel 
PH 102 and Cab-0-Sil were weighed and sieved through a sieve of mesh size 40. The 
ingredients of the formulation were mixed in the desired ratio, according to the 
formulation (Table 1) for 1 5 minutes in a turbula mixer to achieve a homogeneous 
mixture. 
Lubrication: Magnesium stearate was weighed and passed through a sieve of mesh 
size 80 and added to the above powder blend for lubrication purpose and mixed for an 
additional 5 minutes in the turbula mixer. 
Compaction: Two kinds of tablets were prepared from each of the eight formulations. 
One kind was matrix-mini tablets (round concave, punch size 6 mm in diameter) and 
16 
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Table 1: List of· m ~e ct• d th . d for ei!!ht f1 12.: 1 . 
Ingredients Form# 1 Form# 2 Form#3 Form#4 Form# 5 Form#6 Form#? Form# 8 
Trazodone.HCI 50 75 50 50 75 50 75 75 
HPMCK4M 40 40 50 40 50 50 40 50 
A vice! PH 102 5 5 5 10 5 10 10 10 
........ 
......) 
Magnesium 1 1 1 1 1 1 1 1 Stearatre 
Cab-0-Sil 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Total 96.5 121.5 106.5 101.5 131.5 111.5 126.5 136.5 
All the quantities are in mg 
the other was matrix tablets (round concave, punch size 9 mm in diameter). Two 
matrix-mini tablets from each fommlation were encapsulated into a hard gelatin 
capsule size #2 and put in to basket of USP Dissolution apparatus 1. The matrix tablet 
was prepared by weighing exactly double the quantity of matrix-mini tablet from each 
formulation. Tablets were prepared by direct compression on a Carver Laboratory 
press machine. The compression pressure was adjusted at 3000lb. The hardness was 
ranged from 6.4-6.9 kg for matrix-mini tablets and 5.1-6.0 kg for matrix tablets. 
Friability was ranged from 0.8-0.9% for matrix-mini tablets and 0.5-0.6% for matrix 
tablets. The surface areas of tablets prepared from eight formulations were given in 
Table 2. 
2.3.3 TABLET EVALUATION 
In vitro Dissolution: 
The in vitro drug release was studied in various pH media in order to simulate in vivo 
dissolution behavior. The solution pH values selected were 1.2, 5 and 7.4. The 
dissolution was carried out using USP apparatus I (basket method). Six tablets were 
tested from each formulation. The volume of the media was 900 ml in each cylinder 
and 50 rotations per minute (rpm) was maintained. The temperature of the dissolution 
medium was maintained at 37±0.5° C. The dissolution tests were carried out for total 
of 24 hrs, in which pH was maintained at 1.2 for first 1 hr, pH 5 for next 5 hrs (pH was 
increased using 4.6 gms of sodium phosphate tribasic/900 ml) and pH 7.4 for 
remaining 16 hrs (pH was increased using 4.8 gms of sodium phosphate tribasic/900 
ml). Samples of 4ml were taken from each cylinder at the interval of 0.5, 1, 2, 4, 6, 8, 
18 
-
"' 
Table 2: Surface area (mm2) of tablets 
Formulation # 
1 
2 
3 
4 
5 
6 
7 
8 
Matrix-mini tablets Matrix tablets 
263.97 220.87 
268.89 224.10 
265.33 221.65 
268.65 221.27 
269.68 224.44 
265.53 221.68 
269.31 224.15 
272.02 224.70 
12, 18, and 24 hr. The collected samples were filtered and analyzed at A.max 312 nm 
using spectrophotometer. 
2.3.4 EXPERIMENTAL DESIGN 
A 2 3 full factorial design was employed to study the effect of different formulation 
variable on tablet release. The three independent variables were selected after primary 
screening for the study are summarized in Table 3. X1 represents the amount of 
trazodone, X2 is amount of HPMC and X3 is the amount of Avicel PH 102. All other 
processing and formulation variables remained constant throughout the study. Table 4 
lists a total of 8 experiments required for a 23 full factorial design. All the three 
variables are kept at two levels- high ( +) and low (-). The response parameters are Y 1, 
Tso (time required to release 5 0% oft he drug from the formulation); Y 2, T 90 (time 
required to release 90% of the drug from the formulation). 
Table 3: List of factors and their range 
+1 -1 
Factors: 
Max Min 
X1: Amount of drug (mg) 75 50 
X2 : Amount ofHPMC K4M (mg) 50 40 
X3: Amount of Avicel PH 102 (mg) 10 5 
20 
N 
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Table 4: 23 full factorial design 
Form# X1 (trazodone) 
1 -
2 + 
3 
-
4 -
5 + 
6 
-
7 + 
8 + 
X2(HPMC) X3 (Avicel) 
- -
- -
+ -
- + 
+ -
+ + 
- + 
+ + 
2.3.5 ANALYSIS OF DATA 
All the statistical and regression analysis procedures for the response parameters were 
performed using a Minitab software package. Statistical analysis includes the 
determination of coefficients of regression equation for each response variable, 
analysis of variance (ANOVA) to determine the significance of each independent 
variable (Xl, X2, and X3), two-way interactions (X1 X2, X2X3, and Xl X3) and three-
way interactions (X1 X2 X3), main effect plots and interaction plots. Contour plots are 
also generated to study the effect of different formulation variables on the response 
parameters. (V astraj et al. 2002). All the experiments were carried out twice to 
perform ANOV A. 
The general linear model used for the experimental design was: 
22 
( 3. RESULTS AND DISCUSSION 
3.1 CALIBRATION CURVE OF TRAZODONE HYDROCHLORIDE IN 
DIFFERENT BUFFERS 
Table 5 illustrates the absorbencies of the serial concentrations of trazodone 
hydrochloride in HCl buffer pH 1.2. Figure 2 shows the standard curve of trazodone 
hydrochloride at pH 1.2. The concentration of trazodone hydrochloride in this buffer 
was calculated using the following equation. 
Concentration (mcg/ml) (Absorbance - 0.016) I 0.0082 (Eqn. 1) 
Table 6 illustrates the absorbencies of the serial concentrations of trazodone 
hydrochloride in phosphate buffer pH 5.0. Figure 3 shows the standard curve of 
trazodone hydrochloride at pH 5.0. The concentration of trazodone hydrochloride in 
this buffer was calculated using the following equation. 
Concentration (mcg/ml) = (Absorbance - 0.002) I 0.0086 (Eqn. 2) 
Table 7 illustrates the absorbencies of the serial concentrations of trazodone 
hydrochloride in phosphate buffer pH 7.4. Figure 4 shows the standard curve of 
trazodone hydrochloride at pH 7.4. The concentration of trazodone hydrochloride in 
this buffer was calculated using the following equation. 
Concentration (mcg/ml) (Absorbance + 0.0099) I 0.0084 (Eqn. 3) 
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Table 5: Standard calibration data for trazodone hydrochloride in HCI buffer (pH 1.2) 
Concentration (mcg/rnl) Absorbance 
0 0 
25 0.223 
50 0.439 
75 0.651 
100 0.839 
125 1.036 
150 1.245 
Figure 2: Standard curve of trazodone hydrochloride in HCl buffer (pH 1.2) 
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Table 6: Standard calibration data for trazodone hydrochloride in phosphate buffer (pH 5.0) 
Concentration (mcg/ml) Absorbance 
0 0 
25 0.213 
50 0.438 
75 0.649 
100 0.86 
125 1.051 
150 1.299 
N 
-J 
Figure 3: Standard curve of trazodone hydrochloride in phosphate buffer (pH 5.0) 
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Table 7: Standard calibration data for trazodone hydrochloride in phosphate buffer (pH 7.4) 
Concentration (mcg/rnl) Absorbance 
0 0 
25 0.205 
50 0.397 
75 0.601 
100 0.827 
125 1.056 
150 1.245 
N 
IO 
Figure 4: Standard curve of trazodone hydrochloride in phosphate buffer (pH 7.4) 
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3.2 DIFFUSIONAL COEFFICIENT 
Hydroxypropylmethyl cellulose (HPMC) is a polymer, which is frequently used in 
sustained release matrices. The mechanism by which it retards drug release center on 
its ability to rapidly form a gel layer around the surface of a matrix exposed to 
aqueous fluids (Alderman, 1984). As the matrix contacts the dissolution medium, the 
polymer undergoes a relaxation process and two fronts are established around the 
matrix: the penetration front and the dissolution front. The penetration front is defined 
as the interface between the non-relaxed polymer and the gel; the dissolution front is 
defined as the interface between the gel and the dissolution medium. At the 
penetration front, the hydration, swelling and coalescence of polymer particles occur, 
whereas at the dissolution front, polymer chain disentanglement and dissolution of the 
hydrated matrix occur (Lee and Peppas, 1987: Harland et al., 1988: Skoug et al., 1993: 
Pham and Lee, 1994: Gao et al. , 1995). 
For drugs with low water solubility, drug release is mainly via erosion; for a soluble 
drug, the drug can dissolve and diffuse through the hydrated gel layer and diffusion is 
predominant (Alderman, 1984; Doelker, 1987; Skoug et al. , 1993). 
Korsmeyer et al. (1983) used a simple empirical equation, Eqn 4, to describe general 
solute release behavior from controlled release polymeric matrices. 
Mt/Moo = k t11 (Eqn.4) 
Where Mt/Moo is the fraction of drug released, k is the drug release constant, t is the 
time and n is the diffusional exponent. Peppas (1985) stated that n is 0.5 for Fickian 
diffusion, 0.5 < n > 1.0 for non-Fickian transport and 1.0 for case II transport. 
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Figure 5 shows the dissolution curve for all eight batches of matrix-mini tablets. Table 
8 shows the dissolution data for eight batches of matrix-mini tablets . Tso and T9o of 
fomrnlations # 2, 5, 7 and 8, which have higher drug load, are longer than remaining 
formulations . Figure 6 shows the dissolution curve for all eight batches of matrix 
tablets. Table 9 shows the dissolution data for eight batches of matrix tablets. 
Tso and T90 of formulations # 2, 5, 7 and 8, which have higher drug load, longer than 
remaining fomrnlations . 
Table 10 compares Tso and T 90 of matrix-mini tablets and matrix tablets. Matrix 
tablets released drug slowly compared to matrix-mini tablets with higher Tso and T90, 
which is a desirable characteristic for controlled release formulations. This may be due 
to higher surface area of matrix-mini tablets (Table 2). 
Table 11 & 12 show the values of n, k and R2 for matrix-mini tablets and matrix tablets 
respectively. The correlation coefficient was greater than 0.95 in most cases indicating 
a good fit of the equation (the results of early drug release 0.5 , 1, 2 hr were omitted, 
because at the beginning of the dissolution study, the drug present on the surface of 
the tablet rapidly comes in to dissolution medium and which is not the case later on). 
All then values lie between 0.5-1.0 indicating a non-Fickian transport (Peppas., 1985). 
Even though n values of matrix tablets were close to 0.89 indicating a zero-order 
release, the total drug release was in the range of 90.00-98 .70%. In the case of matrix-
mini tablets, the total drug release was in the range of 93.02-100%. 
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Figure 5: Dissolution curve of eight batches of trazodone hydrochloride matrix-mini tablets 
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Table 8: Dissolution data for eight batches of trazodone hydrochloride matrix-mini tablets 
Time (hr) Form # 1 Form# 2 Form # 3 Form # 4 Form # 5 Form # 6 
0 0 0 0 0 0 0 
0.5 6.26 ± 1.17 9.54 ± 0.62 7.19 ± 0.53 9.40 ± 1.33 7.61 ± 1.73 8.98 ± 1.00 
1 14.73 ± 0.78 15.33 ± 1.00 15.07 ± 0.49 15.99 ± 1.39 13.15 ± 1.68 15.49 ± 1.26 
2 24.98 ± 0.98 23.26 ± 0.66 23.88 ± 0.57 26.49 ± 1.11 22.02 ± 1.60 26.23 ± 1.56 
4 43.50 ± 1.83 37.13 ± 0.94 42.28 ± 1.61 43 .90 ± 1.70 36.14± 1.71 43 .10 ± 2.32 
6 57.19 ± 2.11 48.10 ± 1.35 55.10 ± 1.82 57.87 ± 1.81 48.98 ± 1.72 56.83 ± 1.72 
8 73.03 ± 2.56 60.68 ± 1.39 68.97 ± 2.25 69.76 ± 1.87 58.06 ± 1.79 72.56 ± 2.51 
12 82.29 ± 4.64 73 .12 ± 2.47 85 .19 ± 2.55 84.17 ± 1.78 70.78 ± 2.39 85.56 ± 1.76 
18 96.06± 7.24 86.21±5.17 98.38 ± 2.67 100 ± 3.53 86.87 ± 2.73 98.20 ± 1.62 
24 99.33 ± 5.75 93.02 ± 2.85 100 ± 1.08 100 ± 1.10 93.87 ± 3.36 100±0.94 
Dissolution data in % average release± SD 
Form # 7 Form # 8 
0 0 
10.41 ± 0.56 9.46 ± 0.71 
17.62 ± 0.56 16.40 ± 0.90 
25.20 ± 1.97 23.12 ± 1.02 
38.98 ± 0.99 37.20 ± 1.18 
51.84 ± 1.07 47.77 ± 1.20 
64.65 ± 1.38 58.92 ± 1.49 
78.10 ± 2.21 72.27 ± 2.21 
92.28 ± 2.56 86.67 ± 2.54 
99.79 ± 2.52 93.74 ± 2.23 
Figure 6: Dissolution curve for eight batches of trazodone hydrochloride matrix tablets 
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Table 9: Dissolution data for eight batches of trazodone hydrochloride matrix tablets. 
Time (hr) Form # 1 Form #2 Form # 3 Form #4 Form# 5 
0 0 0 0 0 0 
0.5 10.32 ± 0.43 8.39 ± 0.32 9.24 ± 1.71 10.85 ± 1.14 7.04 ± 1.38 
l 15.53 ± 0.19 13.01± 0.6 13.57 ± 0.72 16.70 ± 0.95 10.66 ± 0.36 
2 22.87 ± 0.44 20.06± 1.00 24.38 ± 1.30 22.92 ± 0.97 17.31±0.41 
4 36.19 ± 0.93 30.58 ± 0.94 38.28 ± 1.06 37.60 ± 0.78 28.88 ± 0.79 
6 47.22 ± 2.01 40.36± 0.62 50.28 ± 1.92 49.34 ± 0.98 37.79 ± 1.06 
8 61.49 ± 0.97 51.37± 1.05 59.76 ± 1.94 59.65 ± 1.52 46.99 ± 1.23 
12 75.28 ±1.77 66.39 ± 1.35 72.35 ± 2.03 75.40 ± 1.22 59.97 ± 1.43 
18 88.78 ± 1.30 85.35 ± 1.46 86.17 ± 2.04 90.53 ± 3.79 79.14 ± 3.35 
24 96.83 ± 1.58 92.81 ± 1.57 97.79 ± 3.05 98.70 ± 1.43 90.83 ± 2.41 
Dissolution data in % average release± SD 
Form # 6 Form # 7 Form# 8 
0 0 0 
9.44 ± 1.06 7.56 ± 0.28 7.02 ± 0.85 
13.10 ± 1.14 11.77 ± 1.50 10.90 ± 0.37 
20.88 ± 1.08 17.64 ± 0.37 16.63 ± 0.38 
34.88 ± 1.26 28.17±0.76 27 .02 ± 1.56 
46.31 ± 1.57 38.63 ± 1.26 38.03 ± 1.33 
56.53 ± 1.87 51.89 ± 2.83 50.92 ± 2.84 
66.81±4.22 60.43 ± 1.64 57.53 ± 2.59 
83.15 ± 2.45 81.93 ± 1.47 80.97 ±4.47 
93 .95 ± 4.27 90.90±2.07 90.00 ± 3.71 
(.;.) 
0\ 
,,.--
Table 10: Comparison of T50 & T90 of matrix-mini tablets and matrix tablets 
Form# 1 Form# 2 Form# 3 Form#4 Form# 5 
Time 
(hr) M.M Mat M.M Mat M.M Mat M.M Mat M.M Mat 
Tab Tab Tab Tab Tab Tab Tab Tab Tab Tab 
Tso 4.95 6.3 6.1 6.3 5.2 6.0 4.8 6.1 5.95 8.1 
T90 14.9 16.3 18.7 23.0 14.25 17.4 13.95 16.7 19.5 23.5 
M.M. Tab- matrix-mini tablet, Mat.Tab- matrix tablet 
Form#6 Form#? Form# 8 
M.M Mat M.M Mat M.M Mat 
Tab Tab Tab Tab Tab Tab 
4.9 6.3 5.7 7.3 4.5 8.5 
13.7 17.3 16.l 18.0 20.05 22.5 
w 
-...) 
' 
Table 11: Values of kinetic constant (k), release exponent (n) and correlation coefficient (R2) following linear regression of 
dissolution data analyzed by equation 4 for matrix-mini tablets. 
Form.# n Log k (hf1) R2 
1 0.558 1.291 0.948 
2 0.566 1.229 0.980 
3 0.550 1.258 0.958 
4 0.549 1.306 0.963 
5 0.588 1.202 0.983 
6 0.554 1.300 0.956 
7 0.568 1.257 0.982 
8 0.571 1.222 0.985 
w 
00 
' 
Table 12: Values of kinetic constant (k), release exponent (n) and correlation coefficient (R2) following linear regression of 
dissolution data analyzed by equation 4 for matrix tablets 
Form.# n Log k (hr-1) R2 
1 0.553 1.252 0.972 
2 0.638 1.117 0.989 
3 0.513 1.295 0.990 
4 0.544 1.268 0.985 
5 0.647 1.078 0.998 
6 0.540 1.239 0.989 
7 0.652 1.082 0.982 
8 0.663 1.060 0.979 
l 
3.3 EFFECT OF FORMULATION VARIABLES ON Tso OF MATRIX-MINI 
TABLETS 
Tso indicates the time required to release 50% of the drug from the formulation. Tso 
ranged from 4.5- 6. l hr, in the conducted eight batches of dissolution experiments. 
Figure 7 shows the main effects plot for Tso. Tso was higher at a high concentration of 
drug (75mg) and low concentrations of HPMC (40mg) and Avicel (5mg). Figure 8 
shows the interaction plot of Tso for the matrix mini-tablets, there is an interaction 
between the pairs of all the three variables since the lines in the plot are either 
intersecting with each other or they are not parallel to each other. If the lines are 
parallel to each other, it means there is no interaction between the factors. In order to 
statistically determine the significance of each of the three formulation variables in 
dissolution of the matrix-mini tablets, an ANOVA (analysis of variance) was 
perfom1ed. Table 13 shows ANOYA results for Tso. The ANOVA table shows that the 
amount of drug, HPMC and Avicel were statistically significant at alpha 0.05. All the 
dual interactions ( drug*HPMC, drug* A vicel , HPMC* A vicel) and the three way 
interactions ( drug*HPMC* Avicel) also significantly affected the rate of release of 
drug from the mini tablets. Figure 9 shows the surface wire plot for Tso of the amount 
of drug and the amount of HPMC. The time taken to release 50% of drug was highest 
when the amount of drug was 75 mg and the amount of HPMC was 40 mg. Figure 10 
shows the surface wire plot for Tso of the amount of drug and the amount of Avicel. 
The time taken to release 50% of drug was highest when the amount of drug was 75 
mg and the amount of Avicel was 5 mg. Tukey test was performed for the Tso values 
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Figure 7: Main effects plot of data means of T50 of matrix mini-tablets 
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Figure 8: Interaction plot for data means ofT5o of matrix mini-tablets 
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Table 13: Analysis of variance (ANO VA) of T50 of matrix-mini tablets. 
Source DF Seq SS Adj SS Adj MS F p 
drug 1 1.75562 1.75562 1.75562 295.68 0.000 
HPMC 1 0.39062 0.39062 0.39062 65.79 0.000 
Avicel 1 1.32250 1.32250 1.32250 222.74 0.000 
drug*HPMC 1 0.56250 0.56250 0.56250 94.74 0.000 
~ drug* A vicel 1 0.45562 0.45562 0.45562 76.74 0.000 N 
HPMC* A vice! 1 0.39062 0.39062 . 0.39062 65.79 0.000 
drug*HPMC* A vicel 1 0.16000 0.16000 0.16000 26.95 0.001 
Error 8 0.04750 0.04750 0.00594 
Total 15 5.08500 
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Figure 9: Surface wire plot oftrazodone vs HPMC for T50 of matrix mini-tablets 
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Figure 10: Surface wire plot oftrazodone vs Avicel for T50 of matrix mini-tablets 
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of matrix-mini tablets prepared from eight formulations and the result was given in 
Table 14. The basis of grouping was attributed to the closeness ofT50 values. 
3.4 EFFECT OF FORMULATION VARIABLES ON T9o MATRIX-MINI TABLETS 
T 90 indicates the time required to release 90% of the drug from the formulation . T 90 
ranged from 13.7- 20.05 hr, in the eight batches tested during dissolution experiments. 
Figure 11 shows the main effects plot for T 90. T 90 was higher at high concentrations of 
drug (75mg) and of HPMC (50 mg) and at low concentration of Avicel (5 mg). Figure 
12 shows the interaction plot for T9o, there is an interaction between pair of X 1, X2 
(amount of drug and HPMC respectively) as the lines are not parallel , X2, X3 (amount 
of HPMC and Avicel respectively) as the lines are intersecting with each other. There 
is no interaction between pair Xl , X3 (amount of Drug and Avicel respectively) as the 
lines are almost parallel. Table 15 shows ANOVA results of the T90 .The ANOVA 
table shows that the amount of drug, HPMC and Avicel were statistically significant at 
alpha 0.05 . All the two-way interactions (drug*HPMC, drug*Avicel, HPMC*Avicel) 
and the three way interactions ( drug*HPMC* A vicel) also significantly affected the 
rate of release of drug from the matrix-mini tablets. Figure 13 shows the surface wire 
plot for T 5o of the amount of drug and the amount of HPMC. The time taken to release 
90% of drug was highest when the amount of drug was 75 mg and the amount of 
HPMC was 50 mg. Figure 14 shows the surface wire plot for T 50 of the amount of 
drug and the amount of A vicel. The time taken to release 90% of drug was highest 
when the amount of drug was 75 mg and the amount of Avicel was 5 mg. Tukey test 
was performed for the T9o values of matrix-mini tablets prepared from eight 
45 
Table 14: Tukey test for Tso of matrix-mini tablets 
Means with the same letter are not significantly different*. 
Tukey Grouping Mean (Tso) N Formulation# 
A 6.150 2 2 
A 
• B A 5.975 2 5 
B 
B 5.750 2 7 
c 5.150 2 3 
~ c 0\ 
DC 4.975 2 
D 
D 4.850 2 4 
D 
D E 4.800 2 6 
E 
E 4.525 2 8 
* Minimum significant difference was 0.2926 
.r-
Figure 11 : Main effects plot of data means of T 90 of matrix mini-tablets 
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Figure 12: Interaction plot of data means of T9o of matrix mini-tablets 
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Table 15 : Analysis of variance (ANOVA) ofT90 of matrix-mini tablets 
Source DF Seq SS Adj SS Adj MS F p 
drug 1 76.126 76.126 76.126 l.5E+04 0.000 
HPMC 1 3.610 3.610 3.610 722.00 0.000 
Avicel 1 3.516 3.516 3.516 703.12 0.000 
drug*HPMC 1 8.410 8.410 8.410 1682.00 0.000 
drug* A vice I 1 0.141 0.141 0.141 28.12 0.001 
~ 
HPMC* A vice! 1 3.063 3.063 3.063 612.50 0.000 \0 
drug*HPMC* A vicel 1 1.960 1.960 1.960 392.00 0.000 
Error 8 0.040 0.040 0.005 
Total 15 96.864 
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Figure 13: Surface wire plot oftrazodone vs HPMC for T90 of matrix mini-tablets 
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Figure 14: Surface wire plot of trazodone vs A vi eel for T90 of matrix mini-tablets 
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formulations and the result was given m Table 16. The basis of grouping was 
attributed to the closeness of T 90 values. 
3.5 EFFECT OF FORMULATION VARIABLES ON Tso OF MATRIX TABLETS 
Tso indicates the time required to release 50% of the drug from the formulation. Tso 
ranged from 6.0- 8.9 hr, in the conducted eight batches of dissolution experiments. 
Figure 15 shows the main effects plot for Tso. Tso was higher at high concentrations of 
drug (75mg) and of HPMC (50mg) and at low concentration of Avicel (5mg). Figure 
16 shows the interaction plot for Tso, for the matrix tablets, there is an interaction 
between the pairs of X 1, X2 (amount of drug and HPMC respectively) as the lines are 
not parallel , X2, X3 (amount of HPMC and Avicel respectively) as the lines are 
intersecting with each other. There is no interaction between pair Xl , X3 (amount of 
drug and Avicel respectively) as the lines are almost parallel. In order to statistically 
determine the significance of each of the three formulation variables, an ANOV A 
(analysis of variance) was performed. Table 17 shows ANOVA results for Tso. The 
ANOV A table shows that the amount of drug and HPMC were statistically significant 
at alpha 0.05. All the dual interactions (drug*HPMC, drug* Avicel, HPMC* Avicel) 
and the three way interactions ( drug*HPMC* A vicel) also significantly affected the 
rate of release of drug from the matrix tablets. 
Figure 17 shows the surface wire plot for Tso of the amount of drug and the amount of 
HPMC. The time taken to release 50% of drug was highest when the amount of drug 
was 75 mg and the amount of HPMC was 50 mg. Figure 18 shows the surface wire 
plot for Tso of the amount of drug and the amount of A vice!. The time taken to release 
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Table 16: Tukey test for T90 of matrix-mini tablets 
Means with the same letter are not significantly different* . 
Tukey Grouping Mean (T90) N Fom1ulation # 
A 20.025 2 8 
B 19.575 2 5 
c 18.750 2 2 
V'o 
VJ 
D 16.050 2 7 
E 14.950 2 
F 14.275 2 3 
F 
F 14.025 2 4 
G 13.700 2 6 
* Minimum significant difference was 0.2798 
Vl 
.j::.. 
-...... 
.r:. 
~ 
0 
l{) 
f-
7.8 
7.4 
7.0 
6 .6 
6.2 
,,---
Figure 15 : Main effects plot of data means of T 50 of matrix tablets 
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Figure 16: Interaction plot of data means of T50 of matrix tablets 
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Table 17: Analysis of variance (ANOV A) for T 50 of matrix tablets 
Source DF Seq SS Adj SS Adj MS F p 
drug 1 14.0625 14.0625 14.0625 1406.25 0.000 
HPMC 1 0.3025 0.3025 0.3025 30.25 0.001 
Avicel 1 0.0400 0.0400 0.0400 4.00 0.081 
drug*HPMC 1 0.4225 0.4225 0.4225 42.25 0.000 
V'I 
0\ drug* A vice) 1 0.0900 0.0900 0.0900 9.00 0.017 
HPMC* A vicel 1 0.4900 0.4900 0.4900 49.00 0.000 
drug*HPMC* A vicel 1 0.0900 0.0900 0.0900 9.00 0.017 
Error 8 0.0800 0.0800 0.0100 
Total 15 15 .5775 
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Figure 17: Surface wire plot oftrazodone vs HPMC for T5o of matrix tablets 
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Figure 18: Surface wire plot of trazodone vs A vice! for T5o of matrix tablets 
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50% of drug was highest when the amount of drug was 75 mg and the amount of 
A vicel was 5 mg. Tukey test was performed for the T 50 values of matrix tablets 
prepared from eight formulations and the result was given in Table 18. The basis of 
grouping was attributed to the closeness of T 5o values. 
3.6 EFFECT OF FORMULATION VARIABLES ON T9o MATRIX TABLETS 
T 90 indicates the time required to release 90% of the drug from the formulation. T 90 
ranged from 17.3-23.5 hr, in the eight batches tested during dissolution experiments. 
Figure 19 shows the main effects plot for T90. T9o was higher at high concentrations of 
drug (75mg) and of HPMC (50 mg) and at low concentration of Avicel (5 mg). Figure 
20 shows the interaction plot for T 9o, there is an interaction between all the three 
variables since the lines in the plot are either intersecting with each other or they are 
not parallel to each other. If the lines are parallel to each other, it means there is no 
interaction between the factors. Table 19 shows ANOVA results of the T90 .The 
ANOVA table shows that the amount of drug, HPMC and Avicel were statistically 
significant at alpha 0.05. All the two-way interactions (drug*HPMC, drug*Avicel, 
HPMC* A vice!) and the three way interactions ( drug*HPMC* A vice!) also 
significantly affected the rate of release of drug from the mini tablets. Figure 21 shows 
the surface wire plot for T 5o of the amount of drug and the amount of HPMC. The time 
taken to release 90% of drug was highest when the amount of drug was 75 mg and the 
amount of HPMC was 50 mg. Figure 22 shows the surface wire plot for T 50 of the 
amount of drug and the amount of A vice!. The time taken to release 90% of drug was 
highest when the amount of drug was 75 mg and the amount of A vice! was 5 mg. 
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Table 18: Tukey test for Tso of matrix tablets 
Means with the same letter are not significantly different*. 
Tukey Grouping Mean (Tso) N Formulation# 
A 8.400 2 8 
A 
A 8.150 2 5 
A 
A 8.050 2 2 
B 7.300 2 7 
0\ 
0 
c 6.200 2 
c 
c 6.200 2 6 
c 
c 6.050 2 4 
c 
c 5.950 2 3 
* Minimum significant difference was 0.3957 
Figure 19: Main effects plot of data means of T 9o of matrix tablets 
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Figure 20: Interaction plot of data means of T 90 of matrix tablets 
Trazodone(mg) 
• 75 
• 50 
~ 
--
€' 
, • 
- -- --
--------
HPMC (mg) 
• 50 
• 40 
~ 
' 
--
' 
-
-
~ 
~ 
Avicel (mg) 
~ 
23.0 
20.5 
18.0 
23.0 
20.5 
18.0 
~ 
Table 19: Analysis of variance (ANOVA) for T9o of matrix tablets 
Source DF Seq SS Adj SS Adj MS F p 
drug 1 96.531 96.531 96.531 6177.96 0.000 
HPMC 1 10.726 10.726 10.726 686.44 0.000 
Avicel 1 7.426 7.426 7.426 475.24 0.000 
drug*HPMC 1 2.326 2.326 2.326 148.84 0.000 
0\ drug* Avicel 1 9.456 9.456 9.456 605.16 0.000 \.>.) 
HPMC* A vice! 1 3.516 3.516 3.516 225.00 0.000 
drug*HPMC* A vice[ 1 5.406 5.406 5.406 345 .96 0.000 
Error 8 0.125 0.125 0.016 
Total 15 135 .509 
r---
Figure 21 : Surface wire plot of trazodone vs HPMC for T 90 of matrix tablets 
24 
23 
22 
21 
0\ T90 (hr) 20 ~ 19 
18 
17 
16 
HPMC (mg) 45 
50 
75 T razodone( mg) 
0\ 
Vt 
Figure 22: Surface wire plot of trazodone vs A vice! for T 90 of matrix tablets 
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Table 20: Tukey test for T 90 of matrix tablets 
Means with the same letter are not significantly different* . 
Tukey Grouping Mean (T90) N Formulation # 
A 23.350 2 5 
A 
A 23 .050 2 2 
B 22.550 2 8 
0\ 
0\ c 18.050 2 7 
D 17.300 2 3 
D 
D 17.250 2 6 
E 16.600 2 4 
E 
E 16.200 2 1 
* Minimum significant difference was 0.4946 
.... 
( 
( 
Tukey test was performed for the T 90 values of matrix tablets prepared from eight 
fomrnlations and the result was given in Table 20. The basis of grouping was 
attributed to the closeness of T 90 values. 
4. CONCLUSIONS 
The results of this investigation can be summarized as follows: 
1. Controlled release matrix-mini tablets and matrix tablets of trazodone-
hydrochloride may be prepared by direct compression of the formulation 
ingredients. 
2. Factorial experimental design was demonstrated to be an efficient and effective 
tool for the evaluation of effects of factors and their interaction on the drug release 
from the matrix. 
3. Matrix tablets have longer T50s and T90s than matrix-mini tablets, may be because 
of lower surface areas. 
4. Hydroxypropylmethylcellulose (HPMC) seems to be a good polymer for the 
preparation of controlled release tablets of trazodone hydrochloride. 
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